Stock Comparison
ABBV vs SMMT
AbbVie Inc vs Summit Therapeutics Inc
Who's the better investment? Let's break it down.
The Verdict
SMMT takes this one.
It's not even close. SMMT outscores ABBV by 8.6 points. That's a significant gap in our deep value framework.
Want to compare any two stocks?
Sign up free — get 3 DVR analyses/day, 1800+ stocks, portfolio roast. No credit card.
Valuation
ABBV
Metric
SMMT
Market Cap
P/E Ratio
Lower may indicate better value
Forward P/E
Price/Book
EV/EBITDA
Profitability & Growth
ABBV
Metric
SMMT
Profit Margin
Gross Margin
Operating Margin
Return on Equity
Return on Assets
Revenue Growth
EPS
Financial Health
ABBV
Metric
SMMT
Debt-to-Equity
Lower = less leverage
Current Ratio
Above 1.0 is healthy
Beta
Lower = less volatile
Dividend Yield
Risk Comparison
ABBV
What Could Go Wrong
AbbVie's future growth relies heavily on the continued success and market share expansion of its next-generation immunology drugs, Skyrizi and Rinvoq, which together are projected to reach over $32 bi...
Red Flags
- 🚩Insider Selling Activity: 4 insider sales and 0 purchases in the last 6 months, as per the Quiver so...
- 🚩High R&D Investment for Uncertain Returns: While inherent to pharma, the substantial R&D expenditure...
- 🚩GAAP EPS Volatility: The Q1 2026 GAAP diluted EPS of $0.39, a -45.8% YoY decline due to an unfavorab...
SMMT
Competitive Moat
ABBV
Rating
🛡️ Wide
Trend
➡️ Stable
SMMT
Rating
🛡️ Narrow
Trend
📈 Expanding
Investment Thesis
If AbbVie's key immunology drugs, Skyrizi and Rinvoq, continue to expand their market share globally and achieve their projected combined annual revenue of over $32 billion by 2027, complemented by successful advancements in its neuroscience and oncology pipelines, then the company will sustain mid-to-high single-digit revenue growth and generate substantial free cash flow, supporting its robust d...
Full ABBV AnalysisSummit Therapeutics presents a compelling, high-risk, high-reward investment opportunity driven by ivonescimab's potential to become a blockbuster drug in the massive 2nd-line EGFR mutant NSCLC market. With critical regulatory and clinical catalysts approaching in 2026, strong leadership, and a differentiated mechanism, the company is strategically positioned for significant growth, provided it na...
Full SMMT AnalysisPrice Targets & Strategy
Price Targets & Entry/Exit Strategy
Sign up free to unlock the full comparison
Growth Catalysts
Growth Catalysts Comparison
Sign up free to unlock the full comparison
Market Sentiment
Market Sentiment Analysis
Sign up free to unlock the full comparison
The Deep Dive
AbbVie (ABBV) remains a well-established mega-cap pharmaceutical company, demonstrating stable, incremental growth driven by its robust immunology portfolio, notably Skyrizi and Rinvoq. Q1 2026 results showed modest revenue and adjusted EPS growth, with slightly raised full-year guidance. While financially healthy and a strong dividend payer, its immense market capitalization ($381.10B) and the mature, highly regulated nature of the pharmaceutical industry inherently preclude the possibility of ...
Full ABBV AnalysisSummit Therapeutics continues to hold significant 10x growth potential, primarily driven by its lead asset, ivonescimab, targeting the large US/EU non-small cell lung cancer (NSCLC) market. The bispecific mechanism provides a strong competitive advantage, and key regulatory milestones like the PDUFA date in November 2026 and HARMONi-3 interim data in Q2 2026 serve as major catalysts. The company maintains a robust cash position and positive free cash flow, supporting its clinical development. Ho...
Full SMMT AnalysisWant More Comparisons?
Run any stock through our deep value analyzer.
Not Financial Advice
This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified financial advisor before making investment decisions.